A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)

Terminated

• Conditions: Bladder Cancer; CIS

• Registration Number: NCT01314664
• Lead Sponsor: Endo Pharmaceuticals

Brief Summary

The purpose of this study is to observe and describe the effectiveness and local tolerability of intravesical treatment with valrubicin for non-muscle invasive bladder cancer (NMIBC) in a cohort of subjects treated under routine practice conditions.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-03-11
• Study First Submitted QC: 2011-03-11
• Study First Posted: 2011-03-14
• Study Start: 2011-05
• Primary Completion: 2012-01
• Study Completion: 2012-01
• Status Verified: 2015-06
• Last Update Submitted: 2015-06-10
• Last Update Posted: 2015-06-12

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Males and females 18 years of age and older
• Diagnosed with NMIBC
• Prescribed intravesical valrubicin to treat NMIBC
• Understood and signed Informed Consent to participate

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (10)

BCG Oncology; 🇺🇸 Phoenix, Arizona, United States

Urology Research Network; 🇺🇸 Hialeah, Florida, United States

Advanced Urology Association of Florida; 🇺🇸 Vero Beach, Florida, United States

Delaware Valley Urology; 🇺🇸 Voorhees, New Jersey, United States

Kansas City Urology Care; 🇺🇸 Overland Park, Kansas, United States

Urologic Consultants of SE PA; 🇺🇸 Bala-Cynwyd, Pennsylvania, United States

Long Island Urological Associates; 🇺🇸 Bethpage, New York, United States

Vanderbilt University Medical Center; 🇺🇸 Nashville, Tennessee, United States

Urology Associates of North Texas; 🇺🇸 Arlington, Texas, United States

Urology Clinics of North Texas; 🇺🇸 Dallas, Texas, United States